Market News AIOpen the app

JAZZ stock news · Jazz Pharmaceuticals

Stories about Jazz Pharmaceuticals (JAZZ) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for JAZZ

Follow Jazz Pharmaceuticals (JAZZ) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JAZZ
Free on the App Store and Google Play, or on the web.
  1. Nov 2, 2026, 7:37 PM ET · Results

    Jazz Pharmaceuticals shared its Q3 results, showing record sales of $1.24 billion, up 10% from last year.

    Good for JAZZ

    Jazz Pharmaceuticals reported third-quarter sales of $1.24 billion, up 10%, and raised its 2026 sales forecast to $4.775–$4.85 billion. Strong medicine sales make the outlook stronger.

  2. Sep 15, 2026, 10:10 AM ET · Market

    Jazz Pharmaceuticals says it has finished buying Actio Biosciences.

    Neutral

    Jazz completed the acquisition of Actio in an 8-K. The filing gives no financial or product details, so this is neutral for Jazz.

  3. Aug 10, 2026, 6:05 PM ET · Market

    Jazz Pharmaceuticals plc secures a significant definitive agreement (JAZZ).

    Neutral

    Jazz Pharmaceuticals has filed a Form 8-K indicating entry into a material definitive agreement, which suggests potential strategic developments. The specifics of the agreement will be crucial in determining the overall impact on the company's future performance.